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Abstract
Background: While the factors for poor adherence for treatment with statins have been highlighted, the impact of
their combination on adherence is not clear.
Aims: To estimate adherence for statins and whether it differs according to the number of cardiovascular risk
factors.
Methods: A cohort study was conducted using data from the main French national health insurance system
reimbursement database. Newly treated patients with statins between September 1 and December 31, 2004 were
included. Patients were followed up 15 months. The cohort was split into three groups according to their number
of additional cardiovascular risk factors that included age and gender, diabetes mellitus and cardiovascular disease
(using co-medications as a proxy). Adherence was assessed for each group by using four parameters: (i) proportion
of days covered by statins, (ii) regularity of the treatment over time, (iii) persistence, and (iv) the refill delay.
Results: 16,397 newly treated patients were identified. Of these statin users, 21.7% did not have additional
cardiovascular risk factors. Thirty-one percent had two cardiovascular risk factors and 47% had at least three risk
factors. All the parameters showed a sub-optimal adherence whatever the group: days covered ranged from 56%
to 72%, regularity ranged from 23% to 33% and persistence ranged from 44% to 59%, but adherence was better
for those with a higher number of cardiovascular risk factors.
Conclusions: The results confirm that long-term drug treatments are a difficult challenge, particularly in patients at
lower risk and invite to the development of therapeutic education.
Keywords: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Risk factors, Medication adherence, Databases, Factual,
Pharmacoepidemiology, Insurance, Health, Reimbursement
Background
Coronary Heart Disease (CHD) remains a major cause
of mortality and morbidity in developed countries and
dyslipidemia is one of the risk factors for which drugs
have been marketed. Statins are by far the principal
class used for hypercholesterolemia and their efficacy in
reducing the occurrence of cardiovascular adverse clini-
cal outcomes has been clearly documented during the
last two decades [1-11]. The impact of this class on the
whole drug reimbursement cost has regularly and
dramatically increased during recent years. For example
in France in 2007, reimbursement of statins accounted
for about 800,000 million euros. In this context, the
optimized use and public health impact of this class
becomes a key issue for health policy with regards to
the effectiveness of a drug and its direct and indirect
cost. However, several studies have clearly shown that
the characteristics of patients and treatment patterns
may differ from those of randomized clinical trials: e.g.,
age, gender, dosage and duration of treatment [12-14].
Moreover, several studies have shown poor adherence to
statin treatments and several associated factors have
been highlighted: younger age, insufficient revenue,
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coprescribed drugs [15-24]. Thus, it is essential to iden-
tify all the risk factors and their impact in order to act
on them if possible. While the factors for poor adher-
ence have been highlighted, the impact of their combi-
nation on adherence is not clear. The aim of this study
was to estimate whether adherence differs according to
the number of cardiovascular risk factors.
Methods
Sources of data
This cohort study was performed using anonymous
data from the main French health insurance system:
the Caisse Nationale d’Assurance Maladie des Travail-
leurs Salariés (Cnam-TS) database of the Aquitaine
region of southwest France. This database concerned
2.5 million patients. The Cnam-TS refunds patients
65% of the cost of statin treatment, whatever the type
of drugs or their indication. There is no limitation on
the amount of drugs to be reimbursed. The 35% of the
cost are refunded by a private health insurance. Having
such private insurance is very common in France. The
refund rate is 100% for patients with insufficient
income and for patients suffering from permanent ser-
ious disease such as myocardial infarction. This data-
base has been previously described [25]. Data extracted
from this database were demographic characteristics of
the users, prescribers’ specialty, the name of drugs sub-
mitted for reimbursement and vital status. Conversely,
there is no data regarding diagnosis, daily dose, results
of laboratory data or details regarding stays in public
hospitals.
Population
Patients were included if they submitted a reimburse-
ment form for a prescription for statins between Sep-
tember 1 and December 31, 2004, and did not receive
any statin treatment for 6 months previous to this.
Index date was the date of the first reimbursement
claim for a statin in the database during inclusion per-
iod. There were no exclusion criteria and patients were
followed-up for 15 months after index date.
The new users were split into three groups according
to their number of cardiovascular risk factors that
included age and co-morbidities. In the database, in
addition to statin treatment used as a proxy for the risk
factor hypercholesterolemia, three other risk factors
were identified: age over 50 years for men and 60 for
women, diabetes mellitus, and other cardiovascular dis-
ease (CVD). As the French reimbursement databases do
not include medical data, Diabetes mellitus and CVD
were identified using treatments reimbursed in this indi-
cation as a proxy: insulin and oral hypoglycemiants for
diabetes mellitus and central antihypertensives, beta-
blockers, diuretics, calcium channel blockers, ACE inhi-
bitors, angiotensin II receptor antagonists for CVD.
Thus, three groups were defined:
1 risk factor: patients with hypercholesterolemia (sta-
tin) aged under 50 years for men and 60 years for
women.
2 risk factors: patients with hypercholesterolemia (sta-
tin) with one of the following: aged over 50 years for
men and 60 years for women, diabetes or CVD co-mor-
bidity (the latter were defined using reimbursement of
drugs concomitantly with the statin index date, within a
two-month interval).
At least 3 risk factors: patients with hypercholesterole-
mia (statin) with two or more of the following: aged
over 50 years for men and 60 years for women, diabetes
or CVD co-morbidity.
Prescriber specialty, patient demographic data, vital
status, statins between the September 1, 2004 and June
30, 2006 were collected.
Drug exposure
All drugs were identified in the database according to
the Anatomical Therapeutic Chemical (ATC) classifica-
tion system of the World Health Organization [26]. In
France, all the statins are delivered in non-devisable
units that most-often contain supply for 28 days of
treatment.
Assessment of adherence
Assessing adherence to drug treatments is questionable
if a single criterion is used [27-29]. Therefore, we con-
sidered four criteria: (i) proportion of days covered by
statins (reimbursement of the appropriate quantity of
medication for the considered period of time), (ii)r e g u -
larity of the treatment over time, (iii) persistence of
treatment, and (iv) refill delay.
The proportion of days covered during the study per-
iod (also termed medication availability) was estimated
using the “Continuous Multiple-interval measures of
medication Availability” (CMA) definition [30-33]. The
CMA is defined as the sum of the days’ supply of medi-
cation divided by the number of days between the first
fill and the last refill. The theoretical days’ supply is cal-
culated by dividing the number of units dispensed by
the daily dose for the drug considered, here the studied
statin. The daily dose is the recommended dose per day
for its main indication in adults. The CMA was assessed
both using a cut-off at 80% (a CMA lower than 80%
was considered as unsatisfactory in several previous stu-
dies) and as a continuous variable to characterize the
distribution of the CMA in the study population.
T h er e g u l a r i t yo ft r e a t m e n tw a sa s s e s s e db yc o m p u t -
ing the mean of the Continuous Multiple-interval mea-
sures of medication Gaps (CMG) [31,33], defined as the
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out a day’s supply) and the number of days between the
first and the last prescription reimbursed. Therefore,
CMG is 1 i.e. 100% if there was no gap, i.e.n od r u g
without treatment during the period. CMA and CMG
are restricted to patients with a refill.
The treatment persistence was the percentage of
patients still treated at the end of the period and
described by a Kaplan Meier survival curve analysis [34].
Unlike the two preceding measures, analyses were per-
formed on all patients, even those with only one reim-
bursement. Discontinuation was defined as a minimum
gap of 90 days between the theoretical end date of pre-
scription reimbursed (based on a days’ supply) and the
starting date of the next one. A switch between statins
was not considered as a treatment discontinuation.
The refill delay was assessed by using the delay
between the first two reimbursements. A short delay
was assumed to reflect a good understanding of the
chronic character of the pathology requiring regular and
long-term treatment. Conversely, a long renewal delay
could reflect the patient’s misunderstanding of his
pathology and its management. It could also signal the
occurrence of an adverse effect. The data contained in
the reimbursement database do not allow these two pos-
sibilities to be differentiated.
Follow-up was censored if exceeding the end of the
study period (June 30, 2006), or if a patient died or
moved out of the Aquitaine region.
Ethics/consent
We performed an observational study on anonymous
data. Thus, considering the French legislation, it does
not need to be approved by an ethic committee.
Statistical analysis
Analysis was performed using SAS software version 9.1
for PC; the Student t and Chi tests were used. Kaplan-
Meier analysis was used to estimate persistence rate
since it takes into account censored observations.
Results
Patients and treatment characteristics
16,397 newly-treated patients were included for the
study. Mean age was 61 years and the proportion of
men was 48%. The most delivered drugs were pravasta-
tin (36.3%) and atorvastatin (32.3%) (Table 1). The per-
centage of switches to another statin during the study
period ranged from 1.8% for patients initially treated
with atorvastatin to 3.3% for patients initially treated
with rosuvastatin. Rosuvastatin was the drug towards
which the proportion of switches was the highest (8.4
versus 1.3 to 2.7% for other drugs). General practitioners
were by far the most prevalent prescribers (67.1%)
before cardiologists (4.8%) in second place.
Stratified by cardiovascular risk (CV), 21.7% had one
risk factor (hypercholesterolemia but younger age),
30.9% had two risk factors (hypercholesterolemia with
one of either advanced age or co-morbidity) and 47.4%
three or more risk factors (hypercholesterolemia with
two or more of either advanced age or co-morbity,
Table 1). Patient characteristics were quite different
across CV risk groups: the mean age and proportion of
men significantly increased by number of associated risk
factor (p < 10
-5) and as the percentage of the males also
significantly increased (p < 10
-3) (Table 2). The percen-
tage of deaths during follow-up was 5- to 10-fold higher
in the group with statin and at least two other risk fac-
tors and the difference was statistically significant, while
delay of occurrence of the death seemed to be identical
(Table 2).
Medication adherence in new users
Medication availability
The CMA was better for patients with increasing CV
risk. CMA at 15 months varied from an average of 56%
(67% with a CMA ≤ 80%) for those with one risk factor
to 72% (43.3% with a CMA ≤ 80%) for patients with
t h r e eo rm o r er i s kf a c t o r s( T a b l e3 )a n dt h ed i f f e r e n c e s
were statistically significant.
Regularity
Regularity was better for patients with three or more
risk factors, even if almost one third of the study period
was not covered with the treatment, whatever the group
(Table 3) (p < 10
-3).
Table 1 Newly treated patients and treatment
characteristics
n = 16,397
Patients n, (%)
Male 7,827 (47.7)
Female 8,480 (51.8)
Not available 90 (0.5)
Median age (male) +/-SD 59 years 13.5
Median age (female) +/- SD 63 years 13.8
Initial statin treatment, n (%)
Atorvastatin 5,296 (32.3)
Fluvastatin 1,775 (10.8)
Pravastatin 5,961 (36.3)
Rosuvastatin 791 (4.8)
Simvastatin 2,589 (15.8)
Groups, n (%)
One risk factor (statin alone) 3,560 (21.7)
Two risk factors 5,072 (30.9)
At least three risk factors 7,765 (47.4)
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Persistence rates varied according to groups, and was
significantly worst in those with one risk factor, 44.3%
still being treated at 15 months compared to 50.1% for
those with two risk factors, and 59.4% of those with
three risk factors (Table 3; Figure 1) (p < 10
-3).
Refill delay
Despite the variability of times to first renewal, for the
majority of patients (68%) this was one month.
Discussion
To our knowledge, this study is the first conducted in
France using a reimbursement database and a large
population to assess patterns and adherence to statin
treatment. In this country, reimbursement expenditure
for this therapeutic class represented 6% of all drug
reimbursements in 2007, making assessment of rationale
meaningful. It is also one of the first to explore the
associated CV risk factors, including age and co-morbid
conditions. The results show an overall poor adherence
to treatment in new users with all the parameters
explored. However, adherence increased with the num-
ber of associated risk factors. A working hypothesis is
that patients with several risks are probably more aware
of the risk and more confident in their treatment. This
is supported by the Health Belief Model that predicts a
person will take a health-related action if he/she can
avoid a negative health condition [35].
This is an interesting and innovative approach as the
impact of each risk factor is usually assessed individually
or adherence is compared with regard to the level of
prevention (primary versus secondary) [19,22,36].
As adherence is a multifaceted question, several stan-
dardized parameters were used. These have been exten-
sively discussed in the literature [28,31]. Several remarks
can be made for each parameter studied. Concerning
the availability of medication (CMA), the poor results
observed are in accordance with other studies that have
assessed the CMA [16,23]. One factor that may be
debated is the use of 80% treatment coverage this para-
meter as the cut-off for assessing adherence. This is
commonly used in the literature, yet it may not be
appropriate for all types of drugs [37]. For this reason,
we described CMA both as a categorical (≤ 80%) and
continuous variable (mean CMA with 95% CI). Even so,
the conclusions remain unchanged. Another point is
that if patients with more risk factors are on higher
doses, their theoretical days supply will appear higher
and adherence will appear better. However, in France
the statin dose is the same whatever the number of risk
Table 2 characteristics of the study population with statin according to the group
One risk factor
(statin alone)
n = 3,560
Two risk factors*
n = 5,072
At least three risk factors*
n = 7,765
Total
n = 16,397
Demographic characteristics
Male (%) 1,139 (37.6) 2,374 (46.8) 4,097 (52.8) 7,810 (47.6)
Age (10.1) 31.2 (9.5)
Mean (sd) 45.3 (9.7) 58.8 (10.9) 69.0
Median 46 59 69.0
Extremes 2-59 2-95 18-102
Vital status
Number of deaths during the study period (%) 13 (0.37) 34 (0.67) 294 (3.79)
Mean delay of occurrence (death), months 310 284 283
(Min-max delay, days) (188-433) (224-345) (262-304)
*: other risk factors include age, diabetes mellitus and cardiovascular co-morbidities.
Table 3 adherence to statin treatment for new users
Type of indicator Parameters One risk factor
(statin alone)
Two risk factors* At least three risk factors*
n= 3,560 5,072 7,765
Medication availability CMA, mean % [CI95] 56 [54.7;57.2] 64.4 [63.4;65.5] 72.2 [71.9;73.6]
CMA < 80%, n (%) 2,378 (67.0) 2,889 (57.0) 3,361 (43.3)
Persistence Cumulative rate for persistence
at 15 months % [CI95]
44.3 [42.7;45.9] 50.1 [48.7;51.5] 59.4 [58.3;60.5]
Regularity CMG, mean % [CI95] 33.4 [32.5;34.3] 29.2 [28.5;29.9] 23.2 [22.7;23.8]
Refill delay mean [CI95], days 31.4 [31.0;31.8] 30.2 [29.9;30.5] 28.6 [28.3;28.8]
CMA: Continuous Multiple-interval measures of medication Availability; CMG: Continuous Multiple-interval measures of medication Gaps.
*: other risk factors include age, diabetes mellitus and cardiovascular co-morbidities
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the dose only is changing.
Although not necessarily the case, The CMG values in
this study mirrored the CMA values for each group.
The proportion of persistence at the end of the 15-
month follow-up, i.e.4 4t o5 9 % ,i sc o m p a r a b l et oo t h e r
findings for statins in the literature: 33% at the end of
the first year [38], 47 to 83% at the end of the second
[39-41], 45 to 61% after three years [18,22] and 52 to
83% at five years [42]. Variations across studies appear
to ensue mainly from the population considered, dura-
tion of follow-up and definition of discontinuation. In
the current study, discontinuation was defined as the
absence of any filed statin reimbursement during at
least 90 consecutive days. This period was chosen as a
conservative approach and takes into account the mode
of drug dispensation in France that is often for one
month’s supply. Consideration of a shorter period would
have led to even worse adherence (data not shown).
The CMA results were in accordance with those for
persistence: patients with a CMA ≤ 80% were less per-
sistent, whatever their groups (data not shown). There-
fore, patients who discontinued treatment were likely
the same as those who did not take their medications
regularly, and vice versa. However, even if adherence
was poor, the patients seemed to have a good under-
standing of the value of their treatment, as the delay
between the first and second delivery was as expected, i.
e. one month.
The mean refill delay is slightly higher than expected
if we consider the 28-non-devisable units of the statin’s
boxes. Some explanations for this result are lack of
understanding, occurrence of an adverse event, inability
to get to a pharmacy on time or forgetfulness.
Focusing on treatment patterns, the high percentage
of pravastatin could in part be explained by the fact that
the national health insurance system puts pressure on
physicians to prescribe the cheapest drug of a given
class. The proportion of switches was similar across
molecules except for rosuvastatin, which had the highest
rate of switch towards it. This might reflect the indica-
tion of this drug which is prescribed in France, as a sec-
ond-line therapy.
The poor adherence observed in our study may ensue
from several parameters involving prescribers, patients
or both: lack of confidence between patients and doc-
tors; insufficient explanation about treatment value and
use, a fortiori with such a drug that has no immediate
clinical consequences in case of non-adherence; under-
estimation or denial of the seriousness of the disease
[43]. There are also the adverse effects of statins, mainly
myalgia which if serious, could lead to discontinuation.
The study has several strengths. For instance, the large
number of subjects allowed the comparison of three
groups and the use of a conservative definition of dis-
continuation. Furthermore, a database study is not likely
to alter the behavior of either prescribers or patients.
However, a study conducted using a reimbursement
database suffers from some limitations. Patients may
have been classified as having discontinued if these
move outside the administrative region (Aquitaine) but
this can be considered as only marginal as the popula-
tion over 40 years of age are geographically quite stable.
Discontinuation for financial reasons is also improbable
owing to the extent of the national health insurance sys-
tem, which covers underprivileged and unemployed peo-
ple. Conversely, the cost of statins is high enough to
practically preclude claims for reimbursement not to be
made (mean price: 30 euros, i.e.4 0U S D ,2 8G B P ) .T h e
reimbursement database used here does not include
medical data such as indication or previous medical his-
tory and therefore a proxy was used to define the pre-
sence of diabetes mellitus and CVD. In the USA this is
less of an issue, but health insurance databases cross-
linked to medical databases in European countries
remain exceptions, such as the MEMO in Tayside, Scot-
land [44]. The use of such proxies may be considered as
the greatest limitation of reimbursement database for
this study. However for statins, hypercholesterolemia is
the only indication for this drug, although lipid testing
results were not available in the database. With regards
to CVD co-morbidity, the indications of the drugs used
as proxies were extensive and some may be used for dis-
eases other than CVD (mainly beta-blockers). This may
have led to a minimal number of misclassifications for
those with CVD co-morbity. The event that led patients
to be treated for type II prevention (not investigated
here) may not have been captured by the proxies for CV
risk. If one considers that such events are themselves
risk factors for subsequent events, then these patients
Figure 1 Persistence with statin treatment according to
number of risk factors. (One risk factor: hypercholesterolemia
(statin) and aged under 50 years for men and 60 years for women,
Two risk factors: hypercholesterolemia (statin) with one other
cardiovascular risk factor (age or co-morbidity), Three risk factors:
statin with at least two other cardiovascular risk factors.
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associated risk factors. Taken together with the conser-
vative minimal 90 day period considered for disconti-
nuation, the results presented are likely to be an
underestimation of adherence. In this study, we cannot
explore the extent to which the findings are affected by
adjustment for reimbursement level as in France the
patients do not pay for their statin’ treatments.
At last one must be kept in mind that, as previously
demonstrated [45], the adherence will be probably better
for patients with past prescriptions for medications for
chronic conditions.
Conclusions
Overall, adherence to statins was poor, but better for
those with a higher number of associated CV risk fac-
tors. The results confirm that long-term drug treatments
are a difficult challenge, particularly for patients who
may not see the benefit or feel that they are at risk.
This study is a strong base for the promotion of thera-
peutic education in the cardiovascular field.
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